MedPath

DISE-HNS Effect Study

Not Applicable
Not yet recruiting
Conditions
Obstructive Sleep Apnea
Registration Number
NCT06372847
Lead Sponsor
University Hospital, Antwerp
Brief Summary

The purpose of this study is to assess the site, pattern and degree of upper airway collapse before and during hypoglossal nerve stimulation (HNS) treatment using clinical standard drug-induced sleep endoscopy (DISE) and using a novel, non-invasive method predicting site of collapse from raw polysomnography (PSG) data.

Furthermore, outcomes will be compared between responders and non-responders.

Detailed Description

Patients who will receive hypoglossal nerve stimulation therapy will be recruited at the pre-operative consultation at the department of ENT. As part of the standard procedure, all patients who are eligible for HNS have already undergone DISE.

To be included in the study, the patient should have undergone or is scheduled to undergo a baseline PSG within two years of HNS implantation.

All patients will undergo HNS-implantation and receive HNS-therapy as part of the standard pathway.

One year after HNS-therapy, patients will undergo another PSG as part of routine practice in these patients. An additional DISE will be performed to assess the effect of HNS on the site, pattern and degree of upper airway collapse.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
58
Inclusion Criteria
  • 18 years or older.
  • Eligible for HNS-therapy:
  • AHI between 15 and 65 events/hour
  • BMI under 32 kg/m2
  • Absence of complete concentric collapse of palate (CCC) on DISE
  • Intolerance or failure of continuous positive airway pressure (CPAP)-treatment
  • Intolerance or failure of mandibular advancement device (MAD)-treatment
  • Combination of central and mixed apneas less than 25% of total apneas on recent PSG (not older than two years)
  • Scheduled for HNS-implantation at the Antwerp University Hospital
  • Capable of giving informed consent
  • Baseline polysomnography planned or performed in the last 2 years at the Antwerp University Hospital
Exclusion Criteria
  • Patients will not receive HNS-therapy at the Antwerp University Hospital
  • Known medical history of intellectual disability, memory disorders or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the patient).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Δ%area-of-collapse at the level of the lateral wallsBetween baseline and one year follow-up

The percentage of the area of collapse at the level of the lateral walls - measured using DISE - will be calculated using ImageJ software. The percentage difference of collapse between baseline and one-year follow-up will be calculated.

Secondary Outcome Measures
NameTimeMethod
Non-invasive site and pattern of collapseAt baseline and at one-year follow-up

Non-invasive site and pattern of collapse assessed using the novel developed and validated tool at baseline and 1-year follow-up.

Δ%area-of-collapse at the level of the palate, tongue base and epiglottisBetween baseline and one year follow-up

The percentage of the area of collapse at the level of the palate, tongue base and epiglottis - measured using DISE - will be calculated using ImageJ software. The percentage difference of collapse between baseline and one-year follow-up will be calculated.

Δ%area-of-collapse at each possible site of upper airway collapse (palate, lateral walls, tongue base, epiglottis) in responders and non-respondersBetween baseline and one year follow-up

The Δ%area-of-collapse will be specifically identified in the group of responders and the group of non-responders, to compare these two groups.

DISE-score during baseline DISE and during one-year follow-up DISE.At baseline and at one-year follow-up

DISE-scores (pattern and degree of collapse at each site of upper airway collapse) will be scored to assess the effect of HNS on this outcome.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.